Today: 8 June 2026
Browse Category

NYSE:EXC 2 December 2025 - 15 February 2026

Utilities stocks jump as yields fall: XLU closes at $46.50 heading into Fed minutes week

Utilities stocks jump as yields fall: XLU closes at $46.50 heading into Fed minutes week

U.S. utilities stocks outperformed Friday, with the Utilities Select Sector SPDR Fund (XLU) up 2.8% to $46.50 as bond yields fell after softer inflation data. NextEra Energy rose 2.03% and declared a 10% higher dividend. PJM approved a major transmission line project by NextEra and Exelon. U.S. markets are closed Monday for Washington’s Birthday and reopen Tuesday.
15 February 2026
·····
Constellation Energy stock sinks nearly 7% as PJM price-cap push keeps traders cautious ahead of earnings

Constellation Energy stock sinks nearly 7% as PJM price-cap push keeps traders cautious ahead of earnings

Constellation Energy shares fell 6.7% to $250.46 Wednesday on heavy volume after Washington pressed PJM to cap power prices and speed up grid connections for data centers. The drop came despite Constellation’s recent $7 billion Calpine acquisition, which made it the largest U.S. electricity producer. Other wholesale power stocks also declined, while NextEra Energy rose 1.3%.
5 February 2026
·······
ComEd’s $15.3 billion grid plan could raise Chicago-area bills — what’s in the filing

ComEd’s $15.3 billion grid plan could raise Chicago-area bills — what’s in the filing

Commonwealth Edison submitted a $15.3 billion grid upgrade plan to Illinois regulators, covering 2028–2031. If approved, average residential bills could rise by $2.50 to $3.00 per month starting in 2028. The state review is expected to conclude by year’s end, with a separate rate filing planned for 2027. ComEd says demand is already stressing over 70 substations in its network.
23 January 2026
·
Utilities stocks: XLU slips as Treasury yields climb — PJM price caps, rate cases in focus

Utilities stocks: XLU slips as Treasury yields climb — PJM price caps, rate cases in focus

U.S. utility stocks fell Friday, pulling the Utilities Select Sector SPDR Fund (XLU) down 0.5%, though the ETF still rose about 2% for the week. The 10-year Treasury yield climbed to 4.24%. The White House urged PJM Interconnection to hold an emergency power auction and cap prices amid surging data center demand. Avista filed for a four-year rate increase in Washington, seeking a 13.9% electric and 4.7% gas hike.
18 January 2026
·····
Utilities Stocks Outlook 2026: AI Data Centers, Fed Rate Cuts and Rising Power Bills Put the Sector Back in Focus

Utilities Stocks Outlook 2026: AI Data Centers, Fed Rate Cuts and Rising Power Bills Put the Sector Back in Focus

U.S. utilities stocks end 2025 under scrutiny as electricity bills rise and grid operators warn of supply shortfalls. The Utilities Select Sector SPDR ETF (XLU) shows a forward P/E of about 19.6 and yield near 2.7%, with NextEra Energy as its largest holding. Power demand is set to hit record highs in 2025 and 2026, fueled by data centers and electrification. Investors are watching which companies can grow without sparking political backlash.
25 December 2025
············
Pennsylvania Electric Bills Spike After December 1 Rate Hikes: How Much PECO, PPL and Other Utilities Now Charge

Pennsylvania Electric Bills Spike After December 1 Rate Hikes: How Much PECO, PPL and Other Utilities Now Charge

Pennsylvania electric supply rates rose 3%–11% for most residential customers on December 1, following approval by the state Public Utility Commission. Duquesne Light’s rate jumped 10.6%, while PECO and PPL saw increases of about 6% and 3.7%. Delivery charges remain unchanged. The hikes coincide with higher wholesale power costs and increased demand.
2 December 2025
···

Stock Market Today

  • Tilray Stock Hinges on Canadian and European Cannabis Markets
    June 8, 2026, 9:04 AM EDT. Tilray Brands (TLRY), known for cannabis and beverages, depends heavily on international markets outside the U.S. for revenue and profit. In fiscal 2025, cannabis and wellness made up 38% of sales, with the cannabis division generating $196.9 million-31% of total sales but 44% of gross profit. The company's sales are strongest in Canada and the EMEA region (Europe, Middle East, Africa), benefiting from looser regulations compared to the U.S. Despite a net loss of $67.2 million this year, Tilray's losses have narrowed significantly from the prior period. For Tilray to reach profitability, expanding Canadian and EMEA cannabis revenue remains crucial as U.S. markets face regulatory challenges and declining sales.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Go toTop